NCT01822730

A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis

A Multiple-Center, Randomized, Double-Blind Study of Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Wei Hao · Academic / Other
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Methamphetamine-associated psychosis (MAP) has been considered a pharmacological or environmental pathogen model of schizophrenia (SCZ) due in part to similarities in clinical presentation (i.e. paranoia, hallucinations, disorganized speech, and negative symptoms), response to treatment (e.g.neuroleptics),and pathologic mechanisms (e.g. central dopaminergic neurotransmission) of both conditions. Both paliperidone and risperidone are second generation antipsychotics，but have same pharmacological effects of antipsychotic treatment and paliperidone may have more efficacy and safty.This study was designed to examine the acute efficacy, safety, and tolerability of paliperidone and risperidone for patients with MAP.

Detailed description

Methods:A Multiple-Center, Randomized, Double-Blind.

Conditions

• Methamphetamine Dependence

Interventions

Type	Name	Description
DRUG	paliperidone	Paliperidone group,6mg/pill,6mg-12mg/day non-forced titration method,last 2-4weeks
DRUG	Risperidone	Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks

Timeline

• Start date: 2013-02-01
• Primary completion: 2014-01-01
• Completion: 2014-05-01
• First posted: 2013-04-02
• Last updated: 2015-02-04

Locations

1 site across 1 country: China